


## Diflapolin

<b>Cat. No.:</b>	HY-128171		
<b>CAS No.:</b>	724453-98-9		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>17</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>2</sub> S		
<b>Molecular Weight:</b>	458.36		
<b>Target:</b>	FLAP; Epoxide Hydrolase		
<b>Pathway:</b>	Immunology/Inflammation; Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 83.33 mg/mL (181.80 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.1817 mL	10.9085 mL	21.8169 mL
		5 mM	0.4363 mL	2.1817 mL	4.3634 mL
10 mM		0.2182 mL	1.0908 mL	2.1817 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.54 mM); Suspended solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC <sub>50</sub> s of 30 and 170 nM, respectively, and suppressed the activity of isolated sEH (IC <sub>50</sub> =20 nM) <sup>[1]</sup> .
<b>In Vivo</b>	Diflapolin (1-10 mg/kg; i.p.; 30 min before zymosan injection) exhibits potent anti-inflammatory properties in in-vivo experiments <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male CD-1 mice (zymosan-induced peritonitis mouse model) <sup>[1]</sup>
Dosage:	1, 3 and 10 mg/kg
Administration:	I.p.; 30 min before zymosan injection
Result:	Induced a significant reduction of LTC <sub>4</sub> and LTB <sub>4</sub> peritoneal levels, starting from the dose of 1 mg/kg and comparable to the effect of MK886.

## CUSTOMER VALIDATION

- J Pharm Sci. 29 October 2021.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Garscha U, et al. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase. Sci Rep. 2017;7(1):9398. Published 2017 Aug 24.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA